ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
34
views
0
references
Top references
cited by
5
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
3,499
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer
Author(s):
Y.L. WU
,
M Tsuboi
,
J He
,
YL WU
,
M. TSUBOI
,
J. HE
,
JD Goldman
,
DC Lye
,
DS Hui
,
DCB Lye
,
KM Marks
,
R. BRUNO
,
R Montejano
Publication date:
2020
Journal:
N Engl J Med
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
oa repository (via OAI-PMH doi match)
oa repository (via OAI-PMH doi match)
oa repository (via pmcid lookup)
Powered by
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Cancer Immunotherapy
Author and article information
Journal
PubMed ID::
32955177
DOI::
10.1056/NEJMoa2015301
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
3,499
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib † †Electronic supplementary information (ESI) available: p K a shift for Cys797; geometries of TSs identified with QM/MM calculations; analysis of the minimum free-energy path for Cys797 alkylation; analysis of MD replicas; convergence for US simulations; replica of simulation of Cys797 alkylation; conformational FESs obtained from each MD replica. See DOI: 10.1039/c7sc04761d
Authors:
D. Callegari
,
K. E. Ranaghan
,
C. Woods
…
Resolving Resistance to Osimertinib Therapy using Afatinib in a NSCLC Patient with an EGFR L718Q Mutation
Authors:
Xue Yang
,
Chuan Yu Huang
,
Rongrong Chen
…
First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
Authors:
Tia Cheunkarndee
,
Matthew Z. Guo
,
Stefanie Houseknecht
…
See all similar
Cited by
5
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
Authors:
V. Di Noia
,
A. D’Aveni
,
E. D’Argento
…
Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries
Authors:
Sugat Adhikari
,
Sitaram Khadka
,
Sadhana Dahal
…
What GI Physicians Need to Know During COVID-19 Pandemic
Authors:
Paul Thuluvath
,
Joseph Alukal
,
Nishal C Ravindran
…
See all cited by